PTK2 and cancer: Since FAK inhibitors decrease tumor growth and metastasis in preclinical models and in initial clinical trials in cancer patients [19, 20] and FAK expression/activity was increased in CR-overexpressing MM cells, cells were exposed to the FAK inhibitor VS-6063.